Guselkumab vs Ustekinumab for stricturing Crohn's disease
Treatments studied
Part of Digestive system clinical trials.
This study compares two medicines, Guselkumab and Ustekinumab, for people with Crohn's disease that causes narrowing (strictures) in the bowel. It aims to find which works better to improve symptoms and avoid the need for more procedures.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old and have moderate to severe Crohn's disease.
- You have had bowel obstruction symptoms (like belly pain after eating) in the past 8 weeks.
- A scan or scope has shown a narrowing (stricture) in your small intestine caused by Crohn's.
- You have not had surgery or balloon dilation for a stricture in the last 6 months.
- You have not used Guselkumab or Ustekinumab in the past year and are not allergic to them.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests ustekinumab, a medicine that calms immune inflammation, to see if it can improve symptoms in people with Crohn’s disease that causes bowel narrowing. It may help if your Crohn’s symptoms come from strictures (narrowed areas) seen on scans or endoscopy.
This study looks at whether guselkumab, a different biologic medicine, can help people with Crohn's disease who have already tried ustekinumab but it didn't work well or caused side effects. It aims to see if switching to guselkumab is safe and effective.
This trial compares two ways to treat narrowed areas (strictures) in the gut caused by Crohn's disease: endoscopic strictureplasty versus balloon dilation. It aims to see which method works better for people whose strictures are manageable with a scope.
This study tracks how well a medication called guselkumab works for people with moderate to severe Crohn's disease who have had surgery to remove part of their intestines. Researchers want to see if this treatment helps prevent the disease from coming back.
This study tests a new treatment for people with Crohn's disease who have lost response to ustekinumab (Stelara). It aims to see if a different dosing or additional treatment can help regain control of symptoms.
This study tests whether guselkumab (a targeted drug) can effectively treat Crohn's disease in the ileum (last part of the small intestine). You will have ultrasound scans and blood tests to measure your response, which may help find the right dose and monitor for bowel healing.
Hear when a new Stricture; Bowel trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.